Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension

Journal of Pharmacological Sciences

Volumn 120, Issue 3, 2012, Pages 206-212

  Saito, Yukihiro ^a   Nakamura, Kazufumi ^a   Miyaji, Katsumasa ^b   Akagi, Satoshi ^a   Mizoguchi, Hiroki ^b   Ogawa, Aiko ^b   Fuke, Soichiro ^c   Fujio, Hideki ^d   Kiyooka, Takahiko ^a   Nagase, Satoshi ^a   Kohno, Kunihisa ^a   Morita, Hiroshi ^a,e   Kusano, Kengo F ^a   Matsubara, Hiromi ^b   Ohe, Tohru ^a   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c Okayama Red Cross Hospital   (Japan)

^d SUWA RED CROSS HOSPITAL   (Japan)

^e TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

Author keywords

Acute vasoreactivity testing; Calcium channel blocker; Pulmonary arterial hypertension

Indexed keywords

AMLODIPINE; BERAPROST; NICARDIPINE;

ACUTE VASOREACTIVITY TESTING; ADULT; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR PROCEDURE; CONTINUOUS INFUSION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEART INDEX; HEART OUTPUT; HEART RATE; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE OVERLOAD; HUMAN; LONG TERM CARE; LUNG ARTERY PRESSURE; LUNG RESISTANCE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; REMISSION; SYSTEMIC VASCULAR RESISTANCE;

EID: 84869390636     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12114FP     Document Type: Article

References (35)

1. Akagi S, Nakamura K, Miyaji K, Ogawa A, Kusano KF, Ito H, et al. Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J. 2010;74:2200-2205.
2. Ohkita M, Tawa M, Kitada K, Matsumura Y. Pathophysiological roles of endothelin receptors in cardiovascular diseases. J Pharmacol Sci. 2012;119:302-313.
3. De Feyter PJ, Kerkkamp HJ, de Jong JP. Sustained beneficial effect of nifedipine in primary pulmonary hypertension. Am Heart J. 1983;105:333-334. (Pubitemid 13188290)
4. Saito D, Haraoka S, Yoshida H, Kusachi S, Yasuhara K, Nishihara M, et al. Primary pulmonary hypertension improved by long-term oral administration of nifedipine. Am Heart J. 1983;105:1041-1042. (Pubitemid 13101321)
5. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
6. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-3111. (Pubitemid 40847788)
7. Partanen J, Nieminen MS, Luomanmaki K. Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine. N Engl J Med. 1993;329:812-813. (Pubitemid 23262544)
8. Barst RJ, Gibbs JSR, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S78-S84.
9. Morales-Blanhir J, Santos S, de Jover L, Sala E, Pare C, Roca J, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med. 2004;98:225-234. (Pubitemid 38262656)
10. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet. 1991;338:1173-1174.
11. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 1982;66:334-338. (Pubitemid 12084983)
12. Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol. 1992;19:1060-1064.
13. Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation. 2008;118:1195-1201.
14. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S20-S31.
15. Landmark K, Refsum AM, Simonsen S, Storstein O. Verapamil and pulmonary hypertension. Acta Med Scand. 1978;204:299-302. (Pubitemid 9030049)
16. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J. 1998;12:265-270. (Pubitemid 28389516)
17. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436.
18. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-2537.
19. Satoh T, Saji T, Watanabe H, Ogawa S, Takehara K, Tanabe N, et al. A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension. Circ J. 2011;75:677-682.
20. Hashimoto K, Nakamura K, Fujio H, Miyaji K, Morita H, Kusano K, et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ J. 2004;68:227-231. (Pubitemid 38405014)
21. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131:1917-1928. (Pubitemid 46981654)
22. Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31:1898-1907.
23. Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med. 2010;104:481-496.
24. Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med. 1995;151:384-389.
25. Nootens M, Schrader B, Kaufmann E, Vestal R, Long W, Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest. 1995;107:54-57.
26. Oliveira EC, Ribeiro AL, Amaral CF. Adenosine for vasoreactivity testing in pulmonary hypertension: a head-to-head comparison with inhaled nitric oxide. Respir Med. 2010;104:606-611.
27. Packer M, Medina N, Yushak M, Wiener I. Detrimental effects of verapamil in patients with primary pulmonary hypertension. Br Heart J. 1984;52:106-111. (Pubitemid 14089506)
28. Crevey BJ, Dantzker DR, Bower JS, Popat KD, Walker SD. Hemodynamic and gas exchange effects of intravenous diltiazem in patients with pulmonary hypertension. Am J Cardiol. 1982;49:578-583. (Pubitemid 14209310)
29. Young TE, Lundquist LJ, Chesler E, Weir EK. Comparative effects of nifedipine, verapamil, and diltiazem on experimental pulmonary hypertension. Am J Cardiol. 1983;51:195-200. (Pubitemid 13220702)
30. Packer M, Medina N, Yushak M. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J Am Coll Cardiol. 1984;4:890-901. (Pubitemid 15206636)
31. Terai M, Takenaka T, Maeno H. Inhibition of calcium influx in rabbit aorta by nicardipine hydrochloride (YC-93). Biochem Pharmacol. 1981;30:375-378. (Pubitemid 11142618)
32. Bristow MR, Ginsburg R, Laser JA, McAuley BJ, Minobe W. Tissue response selectivity of calcium antagonists is not due to heterogeneity of [3H]-nitrendipine binding sites. Br J Pharmacol. 1984;82:309-320. (Pubitemid 14117009)
33. Kumada T, Kawai C, Sasayama S, Kinoshita M, Kawamura K, Kusukawa R, et al. [Clinical efficacy of nicardipine by intravenaous infusion in patients with acute heart gailure. A multicenter randomized double-blind placebo-controlled trial.] Jpn Pharmacol Ther. 1995;23:375-398. (text in Japanese with English abstract)
34. Kinoshita M, Kawai C, Kumada T, Kawamura K, Kusukawa R. [Acute effects of a single dose of intravenous administration of nicardipine hydrochloride in patients with acute heart failure.] Early phase II study. Jpn Pharmacol Ther. 1995;23:345-356. (text in Japanese with English abstract)
35. Hirota Y, Kawai C, Hori R, Okumura K, Kinoshita M, Kumada T, et al. [Intravenous nicardipine infusion for the treatment of acute heart failure. A double blind study for the optimal dose determination (late phase II study).] Jpn Pharmacol Ther. 1995; 23:357-373. (text in Japanese with English abstract)